|
|
Article: Amgen Inc's (Thousand Oaks CA) experimental drug denosumab may help the company rebound from its projected sales decline this year, with tests showing the treatment can stop tumors' spread into bones.(Brief article)
- Article from:
- MondayMorning
- Article date:
- June 22, 2009
CopyrightCOPYRIGHT 2009 MedContent Media, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Amgen Inc's (Thousand Oaks CA) experimental drug denosumab may help the company rebound from its projected sales decline this year, with tests showing the treatment can stop tumors' spread into bones. If approved for use in cancer, denosumab could generate $1.8 billion a year for halting prostate tumors and an added $1.2 billion for breast malignancies, said Yaron Werber, a Citigroup analyst in New York. Amgen expects results from five large human trials this year, including two testing denosumab in cancer, the company said. Amgen's revenue will drop as much as 4% to $14.4 billion this year on ...
Related newspaper, magazine, and journal articles:
|
|
Article: Fashion Fantasy Game and The New York Songwriter's ...
Business Wire;
November 3, 2009 ;
700+ words
... ... FashionFantasyGame.com NEW YORK -- Fashion Fantasy Game (FFG) and The New York Songwriter's Circle ... old Ali Brustofski of New York, NY; 17-year-old Aubrey Caswell of Thousand Oaks, CA; and 17-year-old Maddie ...
|
|